How do I interpret a company's price-to-earnings (PE) ratio?

Just about all investment websites will quote a company's P/E ratio. But what does it actually mean and how can you use it when choosing the next stock to add to your portfolio? 

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The price to earnings multiple – more typically referred to as a share's P/E ratio – is probably the most popular and easily available financial ratio. It is simply a company's price per share divided by its earnings per share (or EPS).

Just about every investment website will quote some form of the P/E ratio – but what does it actually tell you about a company's shares? 

The most straightforward interpretation of a company's P/E ratio is that it tells you how much investors are willing to pay in return for $1 of a company's earnings. Although this begs the obvious question: why would investors be willing to pay more than $1 in exchange for $1 of a company's earnings?

Companies like Nextdc Ltd (ASX: NXT) or Nanosonics Ltd (ASX: NAN) regularly trade at multiples of over 150x earnings (or at a price of $150 per $1 of earnings). What would motivate investors to pay so much in return for so little? 

The key to understanding this phenomenon is that the P/E ratio is quoted based on current earnings.

But when you buy a share in a company, what you are really buying are the rights to a portion of that company's future earnings over the lifetime of your investment – which could be decades.

If you are bullish on a company's earnings outlook you would naturally pay more than its current earnings are worth because you anticipate that those earnings will grow exponentially over the period of your investment. In other words, you're willing to pay a higher amount now based on your theory that you'll get much more back through dividends or capital appreciation in the future. 

If many people share your sentiment about a company's future earnings prospects, this will drive both its share price and its P/E ratio higher.

This is why growth stocks like Nextdc have such high P/E ratios. Something unique about their product offering, or business model, or the industry that they operate in leads investors to believe that they will deliver far higher earnings in the future.  

But it's important to note that not every company achieves its potential, and these forecasted earnings are as yet unrealised – they are simply market expectations – and if present circumstances change those expectations can also quickly change. 

A company's P/E ratio will fall when either its share price falls (perhaps because it's not living up to the hype), or its earnings fail to catch up with market expectations and the company enters its more mature stages – maybe even becoming a blue chip. 

So how do you actually use a P/E ratio? It's quite simple conceptually, but can be subjective in practice, which is where it gets tricky.

Essentially you just have to work out whether you think, based on a company's current share price, you're getting a good deal on its future earnings. But how do you know what a good deal is? 

When answering that question, the most important thing to keep in mind is that the P/E ratio is a relative valuation metric. These metrics include price to book or price to sales multiples, and are often also referred to as comparables.

This is because they don't really tell you much about the intrinsic value of a company's shares – they only really mean anything when compared to the ratios of other companies.  

As an example, take a look at some of the leading healthcare stocks on the ASX.

ResMed Inc (ASX: RMD) currently has a P/E ratio of 38, CSL Limited (ASX: CSL) has a P/E ratio of 45 and Cochlear Limited (ASX: COH) has a P/E ratio of 51. So how do we interpret this?  Is ResMed cheap and Cochlear expensive? Which share should you buy? 

This is where that subjective element comes in – perhaps Cochlear's higher P/E ratio is warranted because its products are so differentiated from its competitors that it will outperform in future. Or maybe ResMed, with its lower P/E ratio, is being overlooked by investors and you should snap it up on the relative cheap. 

Foolish takeaway

Either way, to properly interpret a company's P/E ratio requires that you spend the time to research the company's products, business model, and the industry in which it operates. But, when used properly, the P/E ratio can still be an invaluable tool in your stock selection process.  

Should you invest $1,000 in Fsa Group right now?

Before you buy Fsa Group shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Fsa Group wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Rhys Brock owns shares of Cochlear Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors sent the market higher once again today.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

2 ASX shares I'd buy if the ASX crashes again

I think the best opportunities can be found when the market falls.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Share Market News

These ASX 200 stocks could rise 20% to 35%

These shares could be destined to deliver big returns over the next 12 months according to analysts.

Read more »

View of a mine site.
Broker Notes

How much upside does Macquarie tip for Deterra Royalties shares?

Deterra Royalties offers ASX investors a different way to invest in global mining.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

3 reasons to buy this surging ASX All Ords gold stock today

The ASX All Ords gold stock has doubled investors’ money in 12 months, and this leading expert forecasts more outperformance…

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Broker Notes

Broker reveals outlook for ASX dividend shares amid volatile market

Peter Gardner from Plato Investment Management tells ASX investors where to look for dividend income this year.

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Share Gainers

Why Generation Development, Orica, Pro Medicus, and Zip shares are storming higher today

These shares are having a strong session on Thursday. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why ANZ, Brainchip, Light & Wonder, and Pilbara Minerals shares are falling today

These shares are tumbling on Thursday. But why?

Read more »